contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-number-of-shares-and-votes-in-senzime-ab-publ-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzime är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av system för övervakning och diagnostik inom sjukvården. I portföljen ingår system som används för att automatisera och mäta ämnena glukos och laktat i blod och vävnader. Bolagets produkter riktar sig till sjukvårdsinstitutioner och läkare. Verksamheten är global. Senzime grundades 1999 och har sitt huvudkontor i Uppsala.

Senzime

As previously announced, the board of directors of Senzime resolved on a directed issue of maximum 1,137,500 shares to the company’s chairman of the board Adam Dahlberg on August 24, 2023. The...

<div class="mfn-preamble"><p><strong>As previously announced, the board of directors of Senzime resolved on a directed issue of maximum 1,137,500 shares to the company’s chairman of the board Adam Dahlberg on August 24, 2023. The directed share issue was approved on the extraordinary general meeting on September 20, 2023.</strong></p></div><div class="mfn-body"><p>The directed share issue has now been subscribed, paid for, and registered. The number of shares and votes in Senzime has therefore increased, and as of September 29, 2023, the total number of shares in Senzime amounts to 100,122,614 (previously 98,985,114 shares), with one vote each. The share capital amounts to SEK 12,515,326.75 (previously SEK 12,373,139.25).<br>As of September 29, 2023, Senzime holds no treasury shares.</p></div><div class="mfn-footer mfn-f23cb96ba75a"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Philip Siberg, CEO of Senzime AB<br>Phone: +46 (0) 707 90 67 34, e-mail:&nbsp;<a rel="noopener" href="mailto:philip.siberg@senzime.com">philip.siberg@senzime.com</a><br>&nbsp;<br>Slavoljub Grujicic, CFO<br>Phone: +46 (0) 76 306 60 11, e-mail: <a rel="noopener" href="mailto:slavoljub.grujicic@senzime.com">slavoljub.grujicic@senzime.com</a></p></div><div class="mfn-footer mfn-about mfn-51570c1d0876"><p><strong class="mfn-heading-1">About Senzime</strong></p><hr><p>Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.</p><p>Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI).&nbsp;More information is available at <a rel="noopener" href="https://senzime.com/">senzime.com</a>.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-29 14:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/57fa8003-732b-4571-af26-d18b7543cd3c/new-number-of-shares-and-votes-in-senzime-ab-publ.pdf" class="mfn-generated mfn-primary">New number of shares and votes in Senzime AB (publ)</a></p></div>